| Frontiers in Medicine | |
| NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials | |
| Medicine | |
| Mustfa Faisal Alkhanani1  Omar E. Hegazi2  Moyad Shahwan2  Ghala Rashid Humaid Alnuaimi2  Samer O. Alalalmeh2  Abdullah Alkhattabi3  Mansour M. Alourfi4  Shaker A. Majrashi5  Nasser M. Alorfi6  Saeed Alsharif7  Ammar Abdulrahman Jairoun8  Hatim Alshahrani9  Faris A. Alsolami1,10  | |
| [1] Biology Department, College of Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia;Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates;Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates;Department of Gastroenterology, East Jeddah Hospital, Jeddah, Saudi Arabia;Department of Gastroenterology, East Jeddah Hospital, Jeddah, Saudi Arabia;Internal Medicine Department, King Faisal Medical City for Southern Region, Abha, Saudi Arabia;Department of Laparoscopic Surgery, King Fahad Hospital, Ministry of Health, Jeddah, Saudi Arabia;Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia;Gastroenterology Department, Armed force hospital of Southern region, Khamis Mushait, Saudi Arabia;Health and Safety Department, Dubai Municipality, Dubai, United Arab Emirates;School of Pharmaceutical Sciences, University Sains Malaysia (USM), Pulau Pinang, Malaysia;Internal medicine Department, Khamis Mushait General hospital, Khamis Mushait, Saudi Arabia;Khulais General Hospital, Makkah cluster, Ministry of Health, Makkah, Saudi Arabia; | |
| 关键词: NAFLD; nutraceuticals; dietary supplements; Omega-3 fatty acids; vitamins; | |
| DOI : 10.3389/fmed.2023.1227046 | |
| received in 2023-05-22, accepted in 2023-06-29, 发布年份 2023 | |
| 来源: Frontiers | |
PDF
|
|
【 摘 要 】
BackgroundNonalcoholic Fatty Liver Disease (NAFLD) has become a significant public health concern, affecting approximately one-fourth of the population. Despite its prevalence, no FDA-approved drug treatments specifically target NAFLD.AimTo provide a review of clinical trials investigating the use of herbal remedies and dietary supplements in NAFLD management, utilizing the ClinicalTrials.gov database.MethodsThis review evaluates the current evidence by examining completed phase III and IV clinical trials registered on ClinicalTrials.gov. An exhaustive search was performed on April 17, 2023, using the terms “Nonalcoholic Fatty Liver Disease” and “NAFLD.” Two independent reviewers appraised eligible trials based on pre-defined inclusion and exclusion criteria.ResultsAn initial search yielded 1,226 clinical trials, with 12 meeting the inclusion criteria after filtration. The majority of trials focused on Omega-3 fatty acids (20.0%) and vitamin D (26.7%), followed by caffeine, chlorogenic acid, ginger, phosphatidylcholine, Trigonella Foenum-graecum seed extract, vitamin C, and vitamin E (each 6.7%). Most studies were Phase 3 (75.0%) and used a parallel assignment model (91.7%). Quadruple masking was the most prevalent technique (58.3%), and Iran was the leading country in terms of trial locations (25.0%). These interventions constitute two herbal interventions and nine supplement interventions.ConclusionThis reveals a diverse range of nutraceuticals, with Omega-3 fatty acids and vitamin D being predominant in the management of NAFLD. The global distribution of trials highlights the widespread interest in these therapeutics. However, more rigorous, large-scale trials are needed to establish safety, efficacy, and optimal dosages.
【 授权许可】
Unknown
Copyright © 2023 Hegazi, Alalalmeh, Alnuaimi, Shahwan, Jairoun, Alorfi, Majrashi, Alkhanani, Alkhattabi and Alourfi, Alsolami, Alsharif and Alshahrani.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202310103972490ZK.pdf | 849KB |
PDF